MEG4Multi-Exponentially Generated 4 (Wave Functions)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Children who received their first dose of MCV4 or polysaccharide vaccine at age 2-6 years because of a high-risk condition and who remain at increased risk for meningococcal disease should be given an additional dose of Meg4 3 years after their first dose.
A small study from Sanofi Pasteur showed slightly higher rates of solicited local and systemic reactions after 7 days among recipients of a second dose of Meg4 compared with those receiving a first dose, but there were no increases in unsolicited adverse events or serious adverse events at 28 days.
Some members of the ACIP expressed concern over the increased risk of Guillain-Barre syndrome (GBS) that has been reported in adolescents who received the Meg4 vaccine, but they agreed that the opportunity to prevent meningococcal disease in more teens trumps the limited data that suggest an association between MCV4 and GBS.